Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma

Published:2009 Issue: Volume: Page:305-311
ISSN:1449-1907
Container-title:International Journal of Medical Sciences
language:en
Short-container-title:Int. J. Med. Sci.

Author:

Kuwahara Akiko,Yamamori Motohiro,Nishiguchi Kohshi,Okuno Tatsuya,Chayahara Naoko,Miki Ikuya,Tamura Takao,Inokuma Tsubasa,Takemoto Yoshiji,Nakamura Tsutomu,Kataoka Kazusaburo,Sakaeda Toshiyuki

Publisher

Ivyspring International Publisher

Subject

General Medicine

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What is the Reason That the Pharmacological Future of Chemotherapeutics in the Treatment of Lung Cancer Could Be Most Closely Related to Nanostructures? Platinum Drugs in Therapy of Non-Small and Small Cell Lung Cancer and Their Unexpected, Possible Interactions. The Review;International Journal of Nanomedicine;2024-09

2. Advancements in steroidal Pt(II) & Pt(IV) derivatives for targeted chemotherapy (2000–2023);European Journal of Medicinal Chemistry;2024-05

3. Emergence of metal-based anticancer therapeutics: A promising perspective;Biomarkers in Cancer Detection and Monitoring of Therapeutics;2024

4. Emerging role of non-coding RNAs in resistance to platinum-based anti-cancer agents in lung cancer;Frontiers in Pharmacology;2023-01-26

5. Platinum anticancer drugs: Targeting and delivery;Comprehensive Inorganic Chemistry III;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP